The results of knockout experiments established that one product of ARS2-directed alternative splicing, PKM2, allows activated CD8+ T cells to fully induce glycolysis, display metabolic flexibility, produce high levels of IFNγ, and mediate efficient antigen-specific control of tumor growth in mice. The gene discussed is CD8A; the disease is neoplasm.